125 related articles for article (PubMed ID: 8534683)
1. Transfer of native insulin through the peritoneal membrane during CAPD in non-diabetic and diabetic patients.
Ersoy FF; Karayalcin U; Karayalcin B; Sapan M; Bozcuk H; Süleymanlar G; Yakupoglu G
Adv Perit Dial; 1995; 11():119-22. PubMed ID: 8534683
[TBL] [Abstract][Full Text] [Related]
2. Differences in fluid and solute transport between diabetic and nondiabetic patients at the onset of CAPD.
Serlie MJ; Struijk DG; de Blok K; Krediet RT
Adv Perit Dial; 1997; 13():29-32. PubMed ID: 9360646
[TBL] [Abstract][Full Text] [Related]
3. Insulin influence (used as an additive to dialysate) on the mitogenic-induced effect of the peritoneal effluent in CAPD patients.
Selgas R; Lopez-Rivas A; Alvaro F; Tarduchy GR; Rueda P; Muñoz J; Vara F
Adv Perit Dial; 1989; 5():161-4. PubMed ID: 2577403
[TBL] [Abstract][Full Text] [Related]
4. [Intermittent peritoneal chronic dialysis in diabetic patients: effect of the technique on blood glucose and protein loss during the procedure].
García Ortiz R; Gómez M; Olea C
Rev Med Chil; 1989 Dec; 117(12):1367-73. PubMed ID: 2519375
[TBL] [Abstract][Full Text] [Related]
5. Peritoneal transport in type I (insulin-dependent) and type II (noninsulin-dependent) diabetic peritoneal dialysis patients.
Lin JJ; Wadhwa NK; Suh H; Cabralda T
Adv Perit Dial; 1995; 11():60-2. PubMed ID: 8534739
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor-1 and peritoneal transport in diabetic and non-diabetic peritoneal dialysis patients.
Lin JJ; Parton L; Bereket G; Wadhwa NK
Clin Nephrol; 1995 Nov; 44(5):310-5. PubMed ID: 8605711
[TBL] [Abstract][Full Text] [Related]
7. High flux peritoneal membrane is a risk factor in survival of CAPD treatment.
Wu CH; Huang CC; Huang JY; Wu MS; Leu ML
Adv Perit Dial; 1996; 12():105-9. PubMed ID: 8865883
[TBL] [Abstract][Full Text] [Related]
8. Serum insulin and insulin-like growth factor binding protein-1 levels in adult patients undergoing peritoneal dialysis.
Iglesias P; Grande C; Méndez J; Fernandez-Reyes MJ; Bajo MA; Selgas R; Díez JJ
Adv Perit Dial; 1996; 12():71-6. PubMed ID: 8865877
[TBL] [Abstract][Full Text] [Related]
9. Increased peritoneal solute transport in diabetic peritoneal dialysis patients.
Lin JJ; Wadhwa NK; Suh H; Cabralda T; Patlak CS
Adv Perit Dial; 1995; 11():63-6. PubMed ID: 8534740
[TBL] [Abstract][Full Text] [Related]
10. Calcium mass transfer and kinetics in CAPD using calcium-free solutions.
Malberti F; Corradi B; Imbasciati E
Adv Perit Dial; 1993; 9():274-9. PubMed ID: 8105942
[TBL] [Abstract][Full Text] [Related]
11. Effect of amino acid based dialysate on peritoneal blood flow and permeability in stable CAPD patients: a potential role for nitric oxide?
Douma CE; de Waart DR; Struijk DG; Krediet RT
Clin Nephrol; 1996 May; 45(5):295-302. PubMed ID: 8738660
[TBL] [Abstract][Full Text] [Related]
12. Measurement of the peritoneal platelet activity through the effluent betathromboglobulin levels in CAPD patients.
Selgas R; Miranda B; Cuesta MV; Garcia-Muñoz S; L-Rivas A; L-Revuel-Ta K; Caparros G; Riñon C; Torre A
Adv Perit Dial; 1990; 6():26-30. PubMed ID: 1982820
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous versus intraperitoneal insulin in the management of diabetics on CAPD: a review.
Tzamaloukas AH; Oreopoulos DG
Adv Perit Dial; 1991; 7():81-5. PubMed ID: 1680463
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of chronic renal insufficiency in the diabetic by dialysis and transplantation].
Legrain M; Rottembourg J; Jacobs C
Diabete Metab; 1985 Feb; 11(1):51-69. PubMed ID: 3884405
[TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal insulin for control of glucose level in insulin dependent diabetic patients treated by CAPD.
Rottembourg J; Balducci A; Baumelou A; Jacq D; Agrafiotis A; Slama G
Proc Clin Dial Transplant Forum; 1980; 10():305-7. PubMed ID: 7050993
[No Abstract] [Full Text] [Related]
16. [Metabolic parameters of CAPD and CCPD in diabetics with terminal renal insufficiency].
Thomae U; Kuhlmann H; Herrmann M; Büchele W
Dtsch Med Wochenschr; 1984 Jun; 109(24):941-4. PubMed ID: 6734446
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal insulin in continuous ambulatory peritoneal dialysis (CAPD): clinical aspects.
Triolo G; Carta Q; Salomone M; Dani F; Passarino G; Boggio Bertinet D; Segoloni GP; Vercellone A
Life Support Syst; 1983; 1 Suppl 1():454-6. PubMed ID: 6400733
[No Abstract] [Full Text] [Related]
18. Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the pathogenesis of steatonecrosis in obesity.
Wanless IR; Bargman JM; Oreopoulos DG; Vas SI
Mod Pathol; 1989 Mar; 2(2):69-74. PubMed ID: 2657721
[TBL] [Abstract][Full Text] [Related]
19. Diabetic patients on CAPD need less aluminum hydroxide as a phosphate binder than non-diabetics.
Macia M; Coronel F; Torrente J; Sanchez A; Tornero F; Barrientos A
Adv Perit Dial; 1990; 6():50-2. PubMed ID: 1982839
[TBL] [Abstract][Full Text] [Related]
20. Glucose, insulin and C-peptide kinetics during continuous ambulatory peritoneal dialysis.
Wideröe TE; Smeby LC; Myking OL; Wessel-Aas T
Proc Eur Dial Transplant Assoc; 1983; 20():195-200. PubMed ID: 6361735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
